Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

4(57.1%)

Phase 2

1(14.3%)

N/A

1(14.3%)

Phase 1

1(14.3%)

7Total

Phase 4(4)

Phase 2(1)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT03083197Phase 4Active Not Recruiting

Scrub Typhus Antibiotic Resistance Trial

Role: collaborator

NCT06575647Phase 4Completed

Vivax Elimination With Tafenoquine (VET) Study

Role: lead

NCT05788094Phase 4Recruiting

ACT vs CQ With Tafenoquine for P. Vivax Mono-infection

Role: lead

NCT04478578Recruiting

Incidences, Causes, and Outcomes of Febrile Illness in Rural South and Southeast Asia

Role: collaborator

NCT02995005Phase 1Completed

Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus

Role: collaborator

NCT03512093Completed

Improving SCBU Care for Preterm Babies

Role: collaborator

NCT03217851Completed

Prevalence Survey of Antimalarial Drug Resistance Markers

Role: collaborator

NCT00495508Phase 4Completed

Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy

Role: collaborator

NCT01872702Not ApplicableCompleted

Targeted Chemo-elimination (TCE) of Malaria

Role: collaborator

NCT02926131Completed

A Study to Evaluate a New Jaundice Stick Test

Role: collaborator

NCT01743820Phase 2Completed

Phase2a Primaquine Dose Escalation Study

Role: collaborator

All 11 trials loaded